This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aastrom Biosciences, Inc. (ASTM)
Q2 2012 Earnings Call
August 7, 2012 4:30 PM ET
Brian Gibson – VP, Finance
Tim Mayleben – President and CEO
Chad Messer – Needham & Company
Keay Nakae – Ascendiant
Steve Brozak – WBB Securities
Jason Kolbert – Maxim
Ladies and gentlemen, thank you for standing by. Welcome to Aastrom Biosciences Second Quarter 2012 Conference Call. At this time, all participants are in a listen-only mode and after opening remarks we will open up for questions. Instructions for queuing up will be provided at that time. I would also like to remind you that this conference is being recorded for replay.
I will now turn the conference over to Brian Gibson, Aastrom’s Vice President of Finance.
Thank you, Michelle, and good afternoon everyone. Welcome to our second quarter 2012 conference call to discuss our most recent financial results and the progress of our development programs.
Before we begin, let me remind you that on today’s call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1995. In any and all of our projections, forward-looking statements represent our judgment as of today. These statements may involve risks and uncertainties that are described more fully in our filings with the SEC, which are also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Joining us on the call today are Aastorm’s President and Chief Executive Officer, Tim Mayleben; and Grayson Wheatley, a cardiovascular surgeon at the Arizona Heart Institute and a principal investigator from the Phase 2b RESTORE-CLI clinical trial and the pivotal Phase 3 REVIVE-CLI clinical trial. Dr. Wheatley is with us today to discuss his experience treating patients of critical limb ischemia and his participation In Aastorm’s clinical development programs for CLI. Following our prepared remarks, we will open the call to your questions.